Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Алексеев, Б. Я.; Нюшко, К. М.; Krasheninnikov, A. A.; Сафронова, Е. Ю.; Сергиенко, С А; Калпинский, А. С.; Воробьев, Н. В.; Каприн, А. Д.

doi:10.17650/1726-9776-2016-12-2-64-73

Cited by 2 publications

(1 citation statement)

References 43 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Распространенность рака предстательной железы (РПЖ), характеризующегося высокими показателями заболеваемости и смертности во всем мире, постоянно увеличивается [1]. В 2018 г. распространенность РПЖ в РФ составила 162,2 случая на 100 тыс.…”

Section: Introductionunclassified

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases

Попов

2020

Medicinskij sovet

View full text Add to dashboard Cite

The prevalence of prostate cancer continues to increase worldwide. The effectiveness of androgen deprivation therapy for advanced prostate cancer has a time limit, after which castration resistance and disease progression are formed. A part of patients with castrate-resistant prostate cancer has no metastases (according to standard imaging methods). The main goal of treatment of these patients is to prolong the time before metastasis formation. This article presents a review of the current understanding of the molecular mechanisms underlying the inhibition of androgen-receptor signaling with enzalutamide, a second-generation androgen receptor antagonist, and the results of clinical studies of its efficacy and safety in castrate-resistant prostate cancer without metastases. It was determined that enzalutamide stimulates the expression of a new class of genes that are not regulated by dihydrotestosterone. It was found that, in addition to inhibiting androgen receptors, enzalutamide can act as a partial transcriptional agonist. Enzalutamide therapy has been shown to reduce the risk of tumor progression and death in patients with non-metastatic castrate-resistant prostate cancer and is well tolerated. Treatment with this drug increases the time before metastases appear, before the first use of subsequent anti-tumor therapy is necessary, and the period before prostate-specific antigen levels have progressed. Study of mechanisms induced by enzalutamide – inhibition of prostate cancer cells growth and activation of genes contributing to cancer development by enzalutamide-related androgen receptor – can help to clarify possible ways of resistance formation to this drug and possibilities of its overcoming with combined therapy.

show abstract

Section: Introductionunclassified

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases

Попов

2020

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

Multiparametric magnetic resonance imaging in diagnosis of local prostate cancer recurrence after radiation therapy and radical prostatectomy: a unified PI-RR reporting system

Rubtsova,

Alekseev,

Kaprin

et al. 2024

Onkourologiâ

View full text Add to dashboard Cite

Multiparametric magnetic resonance imaging (mpMRI) has an indisputable advantage in diagnosis of local recurrences of prostate cancer (PCa). Even though mpMRI has been shown to be very informative for detection of local PCa recurrences, high variability in its application and interpretation remains. Experts from the European Society for Urogenital Radiology (ESUR), the Imaging Committee of the European Association of Urology (ESUI), and several members of the PI-RADS committee developed a unified report system called Prostate Imaging Recurrence Reporting (PI-RR) to measure the risk of local recurrence of PCa in men who have had radical prostatectomy and radiation therapy and are being followed up. The principles of mpMRI that form the basis of PI-RR are well known and are stated in the PI-RADS v.2.1 guidelines, which have proven their diagnostic efficiency. The PI-RR system has the potential to become an important tool for improving communication between specialists involved in the process of PCa diagnosis and treatment, for optimizing treatment strategy in patients with local PCa recurrence, and for improving survival rates in patients with PCa after specialized anticancer treatment.

show abstract

Methods for the diagnosis and treatment of oligometastases in patients with prostate cancer and progressive disease after radical treatment

Cited by 2 publications

References 43 publications

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases

Multiparametric magnetic resonance imaging in diagnosis of local prostate cancer recurrence after radiation therapy and radical prostatectomy: a unified PI-RR reporting system

Contact Info

Product

Resources

About